These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus. Mechlovich D; Amit T; Bar-Am O; Weinreb O; Youdim MB Br J Pharmacol; 2014 Dec; 171(24):5636-49. PubMed ID: 25073425 [TBL] [Abstract][Full Text] [Related]
6. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. Gal S; Zheng H; Fridkin M; Youdim MB J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414 [TBL] [Abstract][Full Text] [Related]
7. The novel multi-target iron chelator, M30 modulates HIF-1α-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice. Mechlovich D; Amit T; Bar-Am O; Mandel S; Youdim MB; Weinreb O Curr Alzheimer Res; 2014 Feb; 11(2):119-27. PubMed ID: 24359498 [TBL] [Abstract][Full Text] [Related]
8. Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1(G93A) Transgenic ALS Mice. Golko-Perez S; Amit T; Youdim MB; Weinreb O J Mol Neurosci; 2016 Aug; 59(4):504-10. PubMed ID: 27173029 [TBL] [Abstract][Full Text] [Related]
9. M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Youdim MB Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S151-4. PubMed ID: 22166418 [TBL] [Abstract][Full Text] [Related]
10. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. Avramovich-Tirosh Y; Amit T; Bar-Am O; Zheng H; Fridkin M; Youdim MB J Neurochem; 2007 Jan; 100(2):490-502. PubMed ID: 17144902 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O Mech Ageing Dev; 2012 May; 133(5):267-74. PubMed ID: 22426424 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging. Bar-Am O; Amit T; Kupershmidt L; Aluf Y; Mechlovich D; Kabha H; Danovitch L; Zurawski VR; Youdim MB; Weinreb O Neurobiol Aging; 2015 Mar; 36(3):1529-42. PubMed ID: 25499799 [TBL] [Abstract][Full Text] [Related]
14. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Zhu W; Xie W; Pan T; Xu P; Fridkin M; Zheng H; Jankovic J; Youdim MB; Le W FASEB J; 2007 Dec; 21(14):3835-44. PubMed ID: 17690154 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo. Piltonen M; Planken A; Leskelä O; Myöhänen TT; Hänninen AL; Auvinen P; Alitalo K; Andressoo JO; Saarma M; Männistö PT Neuroscience; 2011 Sep; 192():550-63. PubMed ID: 21767614 [TBL] [Abstract][Full Text] [Related]
16. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Weinreb O; Amit T; Youdim MB Free Radic Biol Med; 2007 Aug; 43(4):546-56. PubMed ID: 17640565 [TBL] [Abstract][Full Text] [Related]
17. Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease. Salkovic-Petrisic M; Knezovic A; Osmanovic-Barilar J; Smailovic U; Trkulja V; Riederer P; Amit T; Mandel S; Youdim MB Life Sci; 2015 Sep; 136():108-19. PubMed ID: 26159898 [TBL] [Abstract][Full Text] [Related]
18. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411 [TBL] [Abstract][Full Text] [Related]
19. Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation. Hose C; Kaur G; Sausville EA; Monks A Clin Cancer Res; 2005 Sep; 11(17):6370-81. PubMed ID: 16144942 [TBL] [Abstract][Full Text] [Related]
20. Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis. Golko-Perez S; Mandel S; Amit T; Kupershmidt L; Youdim MB; Weinreb O Neurotox Res; 2016 Feb; 29(2):208-17. PubMed ID: 26581376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]